TNB Financial lessened its stake in shares of Danaher Co. (NYSE:DHR) by 27.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,136 shares of the conglomerate’s stock after selling 1,593 shares during the quarter. TNB Financial’s holdings in Danaher were worth $384,000 at the end of the most recent quarter.
A number of other hedge funds have also made changes to their positions in DHR. Aries Wealth Management acquired a new stake in shares of Danaher during the fourth quarter valued at $206,000. Fishman Jay A Ltd. MI lifted its position in Danaher by 6.2% during the fourth quarter. Fishman Jay A Ltd. MI now owns 23,842 shares of the conglomerate’s stock worth $2,213,000 after buying an additional 1,400 shares during the period. Bank of The Ozarks lifted its position in Danaher by 12.0% during the fourth quarter. Bank of The Ozarks now owns 7,385 shares of the conglomerate’s stock worth $685,000 after buying an additional 793 shares during the period. Watch Point Trust Co lifted its position in Danaher by 2.9% during the fourth quarter. Watch Point Trust Co now owns 20,249 shares of the conglomerate’s stock worth $1,879,000 after buying an additional 562 shares during the period. Finally, Calton & Associates Inc. purchased a new position in Danaher during the fourth quarter worth about $114,000. 75.88% of the stock is currently owned by hedge funds and other institutional investors.
DHR has been the topic of a number of research reports. Robert W. Baird restated a “buy” rating and issued a $99.00 price objective on shares of Danaher in a report on Friday, December 15th. Citigroup raised their price objective on Danaher to $107.00 and gave the stock a “buy” rating in a report on Friday, December 15th. Cowen restated a “buy” rating and issued a $110.00 price objective on shares of Danaher in a report on Tuesday, January 30th. UBS Group started coverage on Danaher in a research note on Monday, January 22nd. They issued a “buy” rating and a $99.97 target price for the company. Finally, Stifel Nicolaus reiterated a “buy” rating and issued a $110.00 target price on shares of Danaher in a research note on Friday, January 19th. One analyst has rated the stock with a sell rating, five have issued a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $100.68.
Shares of Danaher Co. (NYSE:DHR) traded up $0.69 during midday trading on Thursday, hitting $96.79. The company had a trading volume of 196,624 shares, compared to its average volume of 2,792,240. The company has a current ratio of 1.43, a quick ratio of 1.05 and a debt-to-equity ratio of 0.39. The company has a market cap of $66,850.00, a P/E ratio of 27.67, a price-to-earnings-growth ratio of 2.00 and a beta of 1.04. Danaher Co. has a 1-year low of $78.97 and a 1-year high of $104.82.
Danaher (NYSE:DHR) last announced its earnings results on Tuesday, January 30th. The conglomerate reported $1.19 earnings per share for the quarter, beating the consensus estimate of $1.16 by $0.03. Danaher had a return on equity of 11.36% and a net margin of 13.60%. The firm had revenue of $5.09 billion for the quarter, compared to the consensus estimate of $4.97 billion. During the same quarter in the previous year, the business earned $1.05 EPS. The firm’s revenue for the quarter was up 10.9% on a year-over-year basis. equities research analysts forecast that Danaher Co. will post 4.37 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which was paid on Friday, January 26th. Stockholders of record on Friday, December 29th were paid a $0.14 dividend. This represents a $0.56 dividend on an annualized basis and a dividend yield of 0.58%. The ex-dividend date of this dividend was Thursday, December 28th. Danaher’s dividend payout ratio is presently 16.00%.
Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.